The
clinical applications of many photosensitizers (PSs) are limited
because of their poor water solubility, weak tissue penetration, low
chemical purity, and severe toxicity in the absence of light. We designed
a novel chlorin-based PS (designated as HPS) to achieve fluorescence
image-guided photodynamic therapy (PDT) with efficient ROS generation.
In addition to its simple fabrication process, HPS has other advantages
such as excellent water solubility, strong NIR absorption, and high
biocompatibility upon chemical functionalization for enhanced phototherapy.
HPS exhibited high photodynamic performance against lung cancer and
breast cancer cells by generating a large amount of singlet oxygen
(1O2) under 654 nm laser irradiation. HPS accumulated
into multiple organelles such as mitochondria and the endoplasmic
reticulum and triggered cell apoptosis by laser exposure. In the tumor-bearing
mice, in vivo, HPS showed an optimal half-life in
circulation and achieved fluorescence-image-guided PDT within the
irradiation window, resulting in effective tumor growth inhibition
and the prolonged survival of animals. Moreover, the antitumor PDT
effect of HPS was close to the clinical trial phase II stage of HPPH
even at the low dosage of 0.32 mg/kg (under 75 J/cm2 laser),
while the systemic safety of HPS was much higher. In conclusion, HPS
is a novel water-soluble chlorin derivative with excellent PDT potential
for clinical transformation.